Compare Invitation Homes Inc. Common Stock (INVH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invitation Homes Inc. Common Stock vs Neurocrine Biosciences Inc — how do they compare? Invitation Homes Inc. Common Stock trades at $26.77 (market cap $15.68B), while Neurocrine Biosciences Inc trades at $136.25 (market cap $13.82B). The key difference: Invitation Homes Inc. Common Stock and Neurocrine Biosciences Inc are close in size by market cap, and Invitation Homes Inc. Common Stock pays a 4.52% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invitation Homes Inc. Common Stock for 0 Days and Neurocrine Biosciences Inc for 24 Days on average.
| INVH | NBIX | |
|---|---|---|
Market Cap | $15.68B | $13.82B |
Volume | 3,619,685 | 1,506,669 |
Sector | Real Estate | Health |
52-Week High | $30.59 | $185.50 |
52-Week Low | $24.39 | $123.10 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $24.13B | $13.83B |
Dividend Yield | 4.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INVH trades at $26.59, down 0.41% on the day, with neutral technical signals and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue growth from $2.73B in 2025 to $2.9B projected for 2026 supports a solid profit margin expansion to 23.13%. Analyst consensus remains bullish with a $31.67 price target, representing 19% upside potential from current levels.
The investment case centers on INVH's consistent earnings outperformance and robust single-family rental demand, though rising interest rates pose headwinds. With 56% of analysts recommending Buy and institutional accumulation continuing, the stock offers value at current levels despite technical consolidation. Key risks include interest rate sensitivity and regulatory changes affecting institutional homebuying.
Neurocrine Biosciences (NBIX) trades at $135.13, down 4.41% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 19.87 and robust profitability, including a net income margin of 20.91% and three consecutive quarterly earnings beats. Recent news highlights pipeline progress and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive given strong earnings momentum and product growth, but risks include execution challenges and pricing pressures. The current price offers a significant discount to the analyst target, presenting a potential opportunity for investors comfortable with the biopharmaceutical sector's inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invitation Homes Inc. Common Stock
Invitation Homes Inc. is a real estate investment trust that acquires, renovates, and leases single-family rental homes across roughly 19 US markets concentrated in Western and Southeastern US. It manages its portfolio through a pod-based local operating model supported by a maintenance technology platform.
Read more on INVH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
